sulforaphane has been researched along with Liver Steatosis in 7 studies
sulforaphane: from Cardaria draba L.
sulforaphane : An isothiocyanate having a 4-(methylsulfinyl)butyl group attached to the nitrogen.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The purpose of this work was to compare the influences of sulforaphane (SFN) to those of the standard insulin sensitizer pioglitazone (PIO) on high fructose diet (HFrD)-induced insulin resistance, dyslipidemia, hepatosteatosis, and vascular dysfunction in rats." | 7.91 | Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats. ( Gameil, NM; Shawky, NM; Shehatou, GSG; Suddek, GM, 2019) |
| "Sulforaphane proved to be an effective in vivo inhibitor of acute ethanol-induced fatty liver in mice." | 7.80 | Sulforaphane induces Nrf2 and protects against CYP2E1-dependent binge alcohol-induced liver steatosis. ( Lin, J; Wu, D; Zhou, R, 2014) |
| "The purpose of this work was to compare the influences of sulforaphane (SFN) to those of the standard insulin sensitizer pioglitazone (PIO) on high fructose diet (HFrD)-induced insulin resistance, dyslipidemia, hepatosteatosis, and vascular dysfunction in rats." | 3.91 | Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats. ( Gameil, NM; Shawky, NM; Shehatou, GSG; Suddek, GM, 2019) |
| "Sulforaphane proved to be an effective in vivo inhibitor of acute ethanol-induced fatty liver in mice." | 3.80 | Sulforaphane induces Nrf2 and protects against CYP2E1-dependent binge alcohol-induced liver steatosis. ( Lin, J; Wu, D; Zhou, R, 2014) |
| "Non-alcoholic fatty liver disease (NAFLD) is a common clinicopathological condition, encompassing a range of conditions caused by lipid deposition within liver cells." | 2.55 | Antioxidant dietary approach in treatment of fatty liver: New insights and updates. ( Di Giacomo, M; Ferramosca, A; Zara, V, 2017) |
| "In Keap1-kd fed an MCDD, steatohepatitis did not develop over the observation periods; however, in Nrf2-null fed an MCDD, the pathological state of the steatohepatitis was aggravated in terms of fatty change, inflammation, fibrosis and iron accumulation." | 1.38 | Nrf2 inhibits hepatic iron accumulation and counteracts oxidative stress-induced liver injury in nutritional steatohepatitis. ( Harada, N; Hashimoto, E; Horie, M; Ishii, T; Itoh, K; Okada, K; Shoda, J; Sugimoto, H; Taguchi, K; Tokushige, K; Ueda, T; Utsunomiya, H; Warabi, E; Yamamoto, M, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (85.71) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Isaacson, RH | 1 |
| Beier, JI | 1 |
| Khoo, NK | 1 |
| Freeman, BA | 1 |
| Freyberg, Z | 1 |
| Arteel, GE | 1 |
| Ferramosca, A | 1 |
| Di Giacomo, M | 1 |
| Zara, V | 1 |
| Shawky, NM | 1 |
| Shehatou, GSG | 1 |
| Suddek, GM | 1 |
| Gameil, NM | 1 |
| Zhou, R | 1 |
| Lin, J | 1 |
| Wu, D | 1 |
| Kikuchi, M | 1 |
| Ushida, Y | 1 |
| Shiozawa, H | 1 |
| Umeda, R | 1 |
| Tsuruya, K | 1 |
| Aoki, Y | 1 |
| Suganuma, H | 1 |
| Nishizaki, Y | 1 |
| Kay, HY | 1 |
| Kim, WD | 1 |
| Hwang, SJ | 1 |
| Choi, HS | 1 |
| Gilroy, RK | 1 |
| Wan, YJ | 1 |
| Kim, SG | 1 |
| Okada, K | 1 |
| Warabi, E | 1 |
| Sugimoto, H | 1 |
| Horie, M | 1 |
| Tokushige, K | 1 |
| Ueda, T | 1 |
| Harada, N | 1 |
| Taguchi, K | 1 |
| Hashimoto, E | 1 |
| Itoh, K | 1 |
| Ishii, T | 1 |
| Utsunomiya, H | 1 |
| Yamamoto, M | 1 |
| Shoda, J | 1 |
1 review available for sulforaphane and Liver Steatosis
| Article | Year |
|---|---|
Antioxidant dietary approach in treatment of fatty liver: New insights and updates.
Topics: Animals; Anthocyanins; Antioxidants; Carotenoids; Catechin; Coumestrol; Curcumin; Energy Metabolism; | 2017 |
1 trial available for sulforaphane and Liver Steatosis
| Article | Year |
|---|---|
Sulforaphane-rich broccoli sprout extract improves hepatic abnormalities in male subjects.
Topics: Adult; Animals; Antioxidants; Biomarkers; Brassica; Dietary Supplements; Disease Models, Animal; Dou | 2015 |
5 other studies available for sulforaphane and Liver Steatosis
| Article | Year |
|---|---|
Olanzapine-induced liver injury in mice: aggravation by high-fat diet and protection with sulforaphane.
Topics: Animals; Antioxidants; Antipsychotic Agents; Body Weight; Chemical and Drug Induced Liver Injury; Di | 2020 |
Comparison of the effects of sulforaphane and pioglitazone on insulin resistance and associated dyslipidemia, hepatosteatosis, and endothelial dysfunction in fructose-fed rats.
Topics: Animals; Aorta, Thoracic; Blood Glucose; Body Weight; C-Reactive Protein; Dyslipidemias; Fatty Liver | 2019 |
Sulforaphane induces Nrf2 and protects against CYP2E1-dependent binge alcohol-induced liver steatosis.
Topics: Animals; Anti-Infective Agents, Local; Anticarcinogenic Agents; Autophagy; Blotting, Western; Cytoch | 2014 |
Nrf2 inhibits LXRα-dependent hepatic lipogenesis by competing with FXR for acetylase binding.
Topics: Acetylesterase; Animals; Blotting, Western; Chromatin Immunoprecipitation; Fatty Liver; Hep G2 Cells | 2011 |
Nrf2 inhibits hepatic iron accumulation and counteracts oxidative stress-induced liver injury in nutritional steatohepatitis.
Topics: Adaptor Proteins, Signal Transducing; Animals; Anticarcinogenic Agents; Choline Deficiency; Cytoskel | 2012 |